Compare Amgen, Inc. (AMGN) vs ARK Innovation ETF (ARKK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs ARK Innovation ETF — how do they compare? Amgen, Inc. trades at $415.33 (market cap $224.14B), while ARK Innovation ETF trades at $80.69. The key difference: Amgen, Inc. pays a 2.43% dividend while ARK Innovation ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | ARKK | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | — |
52-Week High | $417.20 | $92.50 |
52-Week Low | $271.18 | $63.52 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
ARKK trades at $81.51, up 1.3% on the day, with technical indicators showing a bullish trend from moving averages but overbought short-term RSI. The ETF's performance remains challenged by high concentration in speculative growth stocks like Tesla and SpaceX, with no fundamental ratios provided. Recent news highlights Cathie Wood's continued bets on AI and space innovation amid criticism of fees and underperformance versus the S&P 500.
Outlook is cautious due to reliance on a few volatile holdings and premium fees; risks include growth deceleration and market sentiment shifts. Opportunities exist if disruptive bets pay off, but investor patience is required amid potential downside volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →
